Corellation of Mutations, TILs and Age in Breast Cancer

NCT04033965 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 345

Last updated 2019-07-26

No results posted yet for this study

Summary

Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. The investigators investigated the distribution and prognostic effect of mutations (mut) and tumor infiltrating lymphocyte (TILs) in young and elderly early breast cancer patients (pts).

Conditions

Interventions

GENETIC

Corellation of Mutations, TILs and Age in Breast Cancer

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Adamantia Nikolaidi, MD · Oncology Department, MITERA Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-09-03
Primary Completion
2010-10-01
Completion
2010-10-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04033965 on ClinicalTrials.gov